MC
BTCY

Moors & Cabot’s Biotricity, Inc. Common Stock BTCY Stock Holding History

Moors & Cabot’s Portfolio BTCY Stock Details BTCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,667
Closed -$6.38K – 889
2023
Q2 		$6.38K Hold
1,667
– – ﹤0.01% 821
2023
Q1 		$4.65K Hold
1,667
– – ﹤0.01% 847
2022
Q4 		$4.48K Hold
1,667
– – ﹤0.01% 837
2022
Q3 		$8K Hold
1,667
– – ﹤0.01% 807
2022
Q2 		$18K Hold
1,667
– – ﹤0.01% 788
2022
Q1 		$23K Hold
1,667
– – ﹤0.01% 848
2021
Q4 		$40K Hold
1,667
– – ﹤0.01% 847
2021
Q3 		$29K Buy
+1,667
New +$31.3K ﹤0.01% 824

Other funds holding BTCY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SFCL
Strengthening Families & Communities LLC Boston, Massachusetts $450M AUM 41.19% 1-Year Est. Return
AWM
AE Wealth Management Topeka, Kansas $21.5B AUM 26.98% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Moors & Cabot's BTCY Position: Q3 2023 in Review

Moors & Cabot sold out of Biotricity, Inc. Common Stock (BTCY) in Q3 2023, closing a stake of 1,667 shares — an estimated $6.38K sold.

Moors & Cabot first reported a position in BTCY in Q3 2021 and held it in 8 quarters. The position peaked at $40K in Q4 2021. 22 funds tracked by Wall St. Rank hold BTCY as of Q3 2023.

  • Moors & Cabot reported no remaining Biotricity, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Moors & Cabot sold 1,667 Biotricity, Inc. Common Stock shares in Q3 2023, an estimated $6.38K.
  • Moors & Cabot first reported a position in Biotricity, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
  • Moors & Cabot's Biotricity, Inc. Common Stock position peaked at $40K in Q4 2021.
  • 22 funds tracked by Wall St. Rank held Biotricity, Inc. Common Stock as of Q3 2023.

Based on Moors & Cabot's 13F filing for Q3 2023, filed 8 Nov 2023.